Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled

Kyverna Therapeutics, Inc.

Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.
Cash, equivalents and marketable securities $286.0M as of Dec 31, 2024; expected runway into 2027.
FDA aligned on registrational Phase 2 design for KYV-101 in stiff person syndrome; 70% enrolled, topline data 1H 2026.
Phase 2 interim data in myasthenia gravis and Phase 1 data in lupus nephritis expected in 2H 2025.
KYV-102 IND filing planned for 2H 2025; management team and board strengthened.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.